Trio of biotechs raise funds to make en­zymes and de­vel­op drugs for IBS and oth­er au­toim­mune dis­eases

Huili Bio, a Hong Kong-based biotech, has reeled in “hun­dreds of mil­lion RMB,” which equates to at least $15 mil­lion, in a Se­ries A fi­nanc­ing.

The four-year-old start­up is us­ing syn­thet­ic bi­ol­o­gy to com­pu­ta­tion­al­ly de­sign en­zymes. The fi­nanc­ing round will bankroll hir­ing, re­search and de­vel­op­ment for “new prod­uct pipelines” and ramp up the con­struc­tion of “large-scale pro­duc­tion fa­cil­i­ties,” the com­pa­ny said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER